Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
6.300
-0.300 (-4.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch
April 03, 2023
Via
Benzinga
3 Up-and-Coming Growth Stocks to Buy Right Now
March 25, 2023
These companies are small now but could grow much larger over time.
Via
The Motley Fool
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
March 19, 2023
The high-flyers have soared to new heights and further gains could be up ahead.
Via
The Motley Fool
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
March 01, 2023
Via
Benzinga
Could an FDA Approval Send This Stock Flying?
March 01, 2023
Is now the time to load up on this struggling stock?
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
March 01, 2023
Via
Benzinga
Travere Therapeutics's Return On Capital Employed Overview
February 28, 2023
Via
Benzinga
Why Travere Therapeutics Stock Bolted Higher This Week
February 23, 2023
A high-value regulatory approval lit a fire underneath the biotech's shares this week.
Via
The Motley Fool
Travere Therapeutics's Earnings Outlook
February 22, 2023
Via
Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
February 22, 2023
Via
Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
January 30, 2023
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
December 05, 2022
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
December 05, 2022
Via
Benzinga
Recap: Travere Therapeutics Q3 Earnings
October 27, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For February 23, 2023
February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 21, 2023
Via
Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
February 21, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
Via
Benzinga
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
February 01, 2023
These two growth stocks might deliver enormous gains for shareholders this month.
Via
The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
Monday saw 196 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 22, 2022
During Tuesday's trading, 160 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via
Benzinga
Travere Therapeutics Earnings Perspective: Return On Capital Employed
November 03, 2022
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.